Skip to main content

Transplant

Transplant Research Institute

Clinical Trials

Showing 1-9 out of 12 results.
NCT04849728

'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis”
'

Icon for trial | 337HNAS20011 'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and f

This study is currently enrolling.

Inventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and ...

NCT05654922

A Phase 3, Open-Label, Randomized, Standard of Care- Controlled, Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome Progression in Participants with Bilateral Lung Transplant

Icon for trial | RVN-001 A Phase 3, Open-Label, Randomized, Standard of Care- Controlled, Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome Progression in Participants with Bilateral Lung Transplant

This study is currently enrolling.

The purpose of this research study is to see if the investigational drug, ARINA-1 when used with the investigational PARI eFlow nebulizer system, can stabilize or improve the lung function of participants who have had a bilater ...

NCT05500222

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

Icon for trial | MGL-3196-19 A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

This study is currently enrolling.

Madrigal Pharmaceuticals, Inc. has begun a study of an investigational product (also known as the “study drug”) called resmetirom as a possible treatment for NASH cirrhosis. An investigational drug is one that has not been appr ...

NCT04471909

TRIOMPHE - A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch

Icon for trial | CIP009 TRIOMPHE - A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch

This study is currently enrolling.

This study involves research. The purpose of this research study is to continue to test how well the Endospan NEXUS Aortic Arch Stent Graft System performs in the treatment of a diseased aortic arch. The aortic arch is the top ...

NCT04464785

CentriMag Failure-to-Wean Post Approval Study

Icon for trial | ABT-CIP-10336 CentriMag Failure-to-Wean Post Approval Study

You are being invited by your doctor to take part in this research study evaluating the post-market performance of the FDA-approved CentriMag Circulatory Support System because your doctor has determined that this device could ...